Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ascendis Pharma
Biotech
Eyconis launches with $150M and Ascendis' eye disease meds
Frazier, RA Capital and HealthQuest are among the investors financing new eye disease spinout Eyconis.
Max Bayer
Jan 29, 2024 11:03am
Ascendis sells Japan rights to Skytrofa, 2 other drugs for $70M
Nov 29, 2023 8:25am
FDA unexpectedly halts Ascendis' drug review
Apr 3, 2023 10:22am
10 top M&A targets in biotech for 2023
Jan 30, 2023 3:00am
Ascendis scores in phase 3 trial, a boost to endocrine portfolio
Mar 14, 2022 11:15am
Pfizer stumbles close to finish line in growth hormone race
Sep 27, 2021 7:05am